By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Amgen 

Corporate Headquarters
One Amgen Center Drive
Thousand Oaks  California  91320-1789  U.S.A.
Phone: 805-447-1000 Fax: 805-447-1010


SEARCH JOBS


Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

For more information, visit
www.amgen.com and follow us on www.twitter.com/amgen.


Key Statistics


Email:
Ownership: Public

Web Site: Amgen
Employees: 7,300+ Worldwide
Symbol: AMGN
 





Collaborations

Genesis Research and Development Corporation 

Phylos, Inc.  In 2000, Phylos entered into collaboration with Amgen to apply Phylos' PROfusion™ technology to rapidly identify high-affinity binding agents to potential therapeutic targets supplied by Amgen. Amgen will use the sequences and structural information gained through this collaboration for its internal drug discovery programs.

UCB, Inc.  Contract manufacturing of Abarelix peptide active ingredient

EPIX Pharmaceuticals, Inc. 

Dyax Corp.  Antibody phage display





Company News
Amgen (AMGN)'s Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 7/31/2015 11:35:04 AM
Amgen (AMGN) Announces Appointment Of Fred Hassan To Board Of Directors 7/31/2015 10:58:56 AM
Amgen (AMGN) Announces 2015 Third Quarter Dividend 7/29/2015 12:43:37 PM
Amgen (AMGN) Announces Webcast Of 2015 Second Quarter Financial Results 7/28/2015 12:26:46 PM
Allergan (AGN) Could Set its Sights on Another Transformative M&A Deal With Biogen (BIIB), Amgen (AMGN) or AbbVie (ABBV) 7/28/2015 7:25:12 AM
Amgen (AMGN) Release: FDA Approves Kyprolis (carfilzomib) For Combination Use In The Treatment Of Patients With Relapsed Multiple Myeloma 7/24/2015 11:01:44 AM
Amgen (AMGN) Submits Supplemental New Drug Application For Kyprolis (Carfilzomib) In Relapsed Multiple Myeloma 7/23/2015 7:50:44 AM
TraceLink, Inc. Expands Life Sciences Expertise With Former Industry Experts From GlaxoSmithKline (GSK), Amgen (AMGN) And Abbott (ABT) 7/22/2015 11:20:25 AM
Novartis AG (NVS) Thwarted From Selling Amgen (AMGN)'s Neupogen Until September 7/22/2015 6:01:51 AM
European Commission (EC) Approves Amgen (AMGN)s New Cholesterol-Lowering Medication Repatha (Evolocumab), The First PCSK9 Inhibitor To Be Approved In The World, For Treatment Of High Cholesterol 7/21/2015 10:07:09 AM
12345678910...
//-->